TOKYO, July 31 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 29 after discussing its R&D policy at a meeting of the board of directors held on the day and determined the R&D items as follows.
The company intends to actively strengthen R&D in the ophthalmologic & dermatological fields that are its priority and exclusive areas, and promote relevant affiliation, etc. with external entities.
1. Development code UF-021 (eye diseases)
The item in question is isopropyl unoproston, the effective ingredient of "Rescula(R) eyedrop 0.12%" that is marketed as a therapeutic drug for glaucoma and ocular hypertension. This drug is now being developed by R-Tech Ueno for the indication of retinitis pigmentosa. The drug is introduced to Sucampo Pharma Americas Ltd. in the USA to be developed for the indication of atrophic age-related macular degeneration.
2. Development code RTU-007 (eye diseases)
The license is obtained from Astellas Pharma Inc. for the substance to inhibit the enzyme that increases in patients with diabetes mellitus. We intend to proceed with the development of this substance to be indicated for diabetic cataract, diabetic retinopathy and age-related macular degeneration.
3. Development code RU-10 (eye diseases)
Dry eye is targeted for development of the drug that contains gene recombination human serum albumin as an effective ingredient. Though the clinical study is currently interrupted, we intend to look for overseas affiliation soon because the need for treatment of dry eye is globally unmet (that is, there are currently few therapeutic drugs).
4. Development code RK-023 (dermatological diseases)
This item is a physiologically active fatty acid derivative that is a new compound developed by R-Tech Ueno and is being developed as a drug indicated for male
|SOURCE R-Tech Ueno, Ltd.|
Copyright©2009 PR Newswire.
All rights reserved